At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study on Tirofiban With Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction (STRATEGY)
In Brief
A Phase 4 clinical trial evaluating Tirofiban hydrochloride sodium chloride injection, Tirofiban hydrochloride sodium chloride injection placebo, and 1 other intervention for Branch Atheromatous Disease. Completed, enrolled 970 participants across 37 sites.
Detailed Summary
Perforating artery territorial infarction (PAI) refers to a single ischemic lesion in a single perforating arterial territory and branch atheromatous disease (BAD) is an important type. BAD related stroke accounts for 10%-15% ischemic cerebral infarction and is closely related to early neurological deterioration (END). Among patients with single ischemic lesion in other study, dual antiplatelet (clopidogrel plus aspirin) did not significantly reduce the risk of recurrent stroke. The primary purpose of this study is to assess the efficacy and safety of tirofiban combined with aspirin versus placebo combined with aspirin in reducing the risk of stroke and END in patients with BAD.
Study Details
Timeline
Interventions
Day 1: Tirofiban will be given by bolus injection at 0.4ug/kg/min for the first 30 minutes, followed by a continuous infusion at 0.1ug/kg/min for the next 24 hours.
Day 1: Tirofiban placebo will be injected at the same rate with experimental group.
Day 1: Aspirin 100-300mg per day Day 2-90: Aspirin 100mg per day